Array Biopharma Inc.

Genentech, Inc.

Mirati Therapeutics, Inc.

Ventirx Pharmaceuticals, Inc.

Brad Newhouse

James F Blake

Joseph P Lyssikatos

Qian Zhao

Li Ren

Tony P Tang

David A Moreno

John Joseph Gaudino

Ellen Ruth Laird

George T Topalov

Martha E Rodriguez

Adam Wade Cook

Andrew T Metcalf

Mark Laurence Boys

Erik James Hicken

Jonas Grina

Huifen Chen

Laurence Edward Burgess

Shelley Allen

James P Rizzi

Lewis J Gazzard

Jacob Bradley Schwarz

Mark C Munson

Christopher Ronald Smith

Matthew Arnold Marx

David A Mareska

John David Lawson

Kevin W Hunt

John Michael Ketcham

Peter J Mohr

Aaron Craig Burns

Robert Hershberg

Indrani W Gunawardana

Michael Lyon

Robert Kirk DeLisle

Gregory Dietsch

April L Kennedy

Allen A Thomas

Spencer Phillip Pajk

Bryson Rast

James Jeffry Howbert

Jane Schmidt

Julia Haas

Alexandre Joseph Buckmelter

Mark Joseph Chicarelli

Bainian Feng

Wendy B Young

John Peter Fischer

Jay Bradford Fell

Xiaolun Wang

James Gail Christensen

Fredrik Pehr Marmsater

Simon Mathieu

Janet Gunzner

Hong-Woon Yang

Macedonio J Mejia

Joachim Rudolph

Mike Welch

Pavel Savechenkov

Zhaoyang Wen

Joshua Ryan Dahlke

Donghua Dai

Dean Russell Kahn

Steven Mark Wenglowsky

Jacob Matthew O'Leary

Kateri Ahrendt

Joshua D Hansen

Kim Malesky

Josh Hansen

Phong Nguyen

Michael Christopher Hilton

Alan G Olivero

Ronald Jay Hinklin

Barbara J Brandhuber

Jeongbeob Seo

John E Robinson

Hong Woon Yang

Shannon L Winski

Oren T McNulty

Thomas P Bobinski

Guy P A Vigers

Robert Kirk Delisle

Hongqi Tian

Kateri A Ahrendt

Jason De Meese

Fredrik P Marmsäter

Paul Lunghofer

Guy Pa Vigers

Steve Do

Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

KRas G12D inhibitors

Compounds that inhibit KRas G12D; in particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I): or a pharmaceutically acceptable salt thereof.

Provided herein are compounds of the Formula (I): and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein Ring A, X, X, X, R, Rand Rare as defined herein, which are inhibitors of one or more TAM kinases and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor. 

Bicyclic fused pyridine compounds as inhibitors of TAM kinases

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Substituted N-(1H-indazol-4-yl)imidazo[1,2-a]pyridine-3-carboxamide compounds as type III receptor tyrosine kinase inhibitors

The present invention relates to compounds that inhibit KRas G12C. In particular, the present invention relates to compounds that irreversibly inhibit the activity of KRas G12C, pharmaceutical compositions comprising the compounds and methods of use therefor.

KRas G12C inhibitors

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of hyperproliferative, pain and inflammatory diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Serine/threonine kinase inhibitors

Compounds of Formula I or stereoisomers, tautomers, or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein Ring A, Ring C, X, Ra, Rb, Rc, Rd and n are as defined herein, are inhibitors of TrkA kinase and are useful in the treatment of diseases which can be treated with a TrkA kinase inhibitor such as pain, cancer, inflammation/inflammatory diseases, neurodegenerative diseases, certain infectious diseases, Sjogren's syndrome, endometriosis, diabetic peripheral neuropathy, prostatitis or pelvic pain syndrome. 

N-(arylalkyl)-N'-pyrazolyl-urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors

Compounds useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal.

Compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof are provided, which are useful for the treatment of diseases. Methods of using compounds of Formula I or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such diseases, or associated pathological conditions are disclosed. 

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-versus-host disease.

Substituted benzoazepines as toll-like receptor modulators

Compounds of Formula I: and pharmaceutically acceptable salts thereof in which R, R, R, R, Rand Rhave the meanings given in the specification, are inhibitors of cFMS and are useful in the treatment of fibrosis, bone-related diseases, cancer, autoimmune disorders, inflammatory diseases, cardiovascular diseases, pain and burns in a mammal. 

Provided are compositions and methods useful for modulation of signaling through the Toll-like receptors TLR7 and/or TLR8. The compositions and methods have use in treating or preventing disease, including cancer, autoimmune disease, infectious disease, inflammatory disorder, graft rejection, and graft-verses-host disease.

Compounds of Formula I are useful for inhibition of Raf kinases. Methods of using compounds of Formula I and stereoisomers, tautomers, prodrugs and pharmaceutically acceptable salts thereof, for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions are disclosed. 

Pyrazole [3, 4-B] pyridine Raf inhibitors

Growing community of inventors

Boulder, CO, United States of America

Brad Newhouse